LPCN
HEALTHCARELipocine Inc
$2.43+0.10 (+4.29%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LPCN Today?
No stock-specific AI insight has been generated for LPCN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.81$12.37
$2.43
Fundamentals
Market Cap$19M
P/E Ratio—
EPS$-1.77
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume158K
Avg Volume (10D)—
Shares Outstanding8.0M
LPCN News
20 articles- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026Yahoo Finance·May 7, 2026
- Lipocine (LPCN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum DepressionYahoo Finance·Apr 2, 2026
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2025Yahoo Finance·Mar 10, 2026
- Lipocine: Q4 Earnings SnapshotYahoo Finance·Mar 10, 2026
- Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?Yahoo Finance·Feb 27, 2026
- Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Feb 26, 2026
- Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)Yahoo Finance·Feb 18, 2026
- Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15Yahoo Finance·Feb 11, 2026
- Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)Yahoo Finance·Jan 20, 2026
- Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)Yahoo Finance·Jan 12, 2026
- Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment MilestoneYahoo Finance·Dec 16, 2025
- Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)Yahoo Finance·Nov 18, 2025
- Lipocine (LPCN) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance·Nov 6, 2025
- Lipocine: Q3 Earnings SnapshotYahoo Finance·Nov 6, 2025
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025Yahoo Finance·Nov 6, 2025
- Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®Yahoo Finance·Nov 4, 2025
- Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)Yahoo Finance·Sep 30, 2025
- Lipocine to Present at H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 5, 2025
All 20 articles loaded
Price Data
Open$2.30
Previous Close$2.33
Day High$2.35
Day Low$2.26
52 Week High$12.37
52 Week Low$1.81
52-Week Range
$1.81$12.37
$2.43
Fundamentals
Market Cap$19M
P/E Ratio—
EPS$-1.77
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume158K
Avg Volume (10D)—
Shares Outstanding8.0M
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceuticals for the treatment of metabolic and endocrine disorders. The company is headquartered in Salt Lake City, Utah.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—